Table 1.
Overview of potential therapeutic targets and corresponding treatments in uterine sarcomas.
| Therapeutic target | Targeted agents | |
|---|---|---|
| uLMS | HER-2 | HER-2 inhibitors (e.g., trastuzumab, CP-724714, CUDC-101) |
| EGFR | EGFR inhibitors (e.g., gefitinib, erlotinib, cetuximab, vandetanib) | |
| PDGFR | PDGFR inhibitors (e.g., pazopanib, imatinib, sunitinib, sorafenib) | |
| VEGF-VEGFR | VEGF-VEGFR inhibitors (e.g., bevacizumab, aflibercept, vandetanib, cediranib) | |
| IGF1R | Figitumumab, cixutumumab, AVE1642 | |
| BDNF-NTRK2 | BDNF-NTRK2 inhibitors (e.g., K252a) | |
| PIK3/AKT/mTOR Loss of PTEN |
PIK3/AKT/mTOR pathway inhibitors (e.g., curcumin, rapamycin, ridaforolimus) | |
| AURKA | AURKA inhibitors (e.g., MLN8237, MK-5108, VE465) | |
| Wnt/β-catenin | β-catenin inhibitors (e.g., LGK-974, PKF118-310, PNU-74654) | |
| ROR2 | ROR2 inhibitors (not yet developed) | |
| Endoglin/CD105 | Anti-CD105 antibodies (in development) | |
| MDM2 | MDM2 inhibitors (e.g., AMG232, RG7112) | |
| HDAC | HDAC inhibitors (e.g., vorinostat, valproate) | |
| CD47 | Anti-CD47 antibodies (in development) | |
| ER, PR | Aromatase inhibitors (e.g., letrozole, exemestane) Progestins (e.g., medroxyprogesterone acetate, megestrol acetate) |
|
| Loss of TSG | Synthetic lethality principle (e.g., PARP inhibitors) | |
|
| ||
| LGESS | PDGFR | PDGFR inhibitors (e.g., pazopanib, imatinib, sunitinib, sorafenib) |
| EGFR | EGFR inhibitors (e.g., gefitinib, erlotinib, cetuximab, vandetanib) | |
| VEGF-VEGFR | VEGF-VEGFR inhibitors (e.g., bevacizumab, aflibercept, vandetanib, cediranib) | |
| HDAC | HDAC inhibitors (e.g., vorinostat, valproate) | |
| Wnt/β-catenin | β-catenin inhibitors (e.g. LGK-974, PKF118-310, PNU-74654) | |
| ER, PR | Aromatase inhibitors (e.g., letrozole) Progestins (e.g., medroxyprogesterone acetate, megestrol acetate) |
|
|
| ||
| HGESS | 14-3-3 oncoprotein | 14-3-3 oncoprotein inhibitors (not yet developed) |
| PDGFR | PDGFR inhibitors (e.g., pazopanib, imatinib, sunitinib, sorafenib) | |
| HER-2 | HER-2 inhibitors (e.g., trastuzumab, CP-724714, CUDC-101) | |
| EGFR | EGFR inhibitors (e.g., gefitinib, erlotinib, cetuximab, vandetanib) | |
| c-KIT | c-KIT inhibitors (e.g., imatinib, pazopanib) | |
|
| ||
| HGESS/UUS | Tyrosine kinases | Cabozantinib |